Pfizer Inc (PFIZ34) - Total Liabilities
Based on the latest financial reports, Pfizer Inc (PFIZ34) has total liabilities worth R$115.64 Billion BRL (≈ $22.69 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Pfizer Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Pfizer Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Pfizer Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Pfizer Inc balance sheet assets.
Pfizer Inc Competitors by Total Liabilities
The table below lists competitors of Pfizer Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $115.64 Billion |
|
Western Digital Corporation
NASDAQ:WDC
|
USA | $5.00 Billion |
|
Banco Santander S.A
F:BSDK
|
Germany | €1.74 Trillion |
|
Shandong Zhongji Electrical Equipment Co Ltd
SHE:300308
|
China | CN¥18.47 Billion |
|
Danaher Corporation
NYSE:DHR
|
USA | $28.83 Billion |
|
Uber Technologies Inc
NYSE:UBER
|
USA | $33.72 Billion |
|
Welltower Inc
NYSE:WELL
|
USA | $22.29 Billion |
|
Walt Disney Company DRC
BA:DISN
|
Argentina | AR$88.08 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Pfizer Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Pfizer Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pfizer Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pfizer Inc (2014–2025)
The table below shows the annual total liabilities of Pfizer Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | R$121.39 Billion ≈ $23.82 Billion |
-2.81% |
| 2024-12-31 | R$124.90 Billion ≈ $24.51 Billion |
-8.97% |
| 2023-12-31 | R$137.21 Billion ≈ $26.92 Billion |
+35.13% |
| 2022-12-31 | R$101.55 Billion ≈ $19.92 Billion |
-2.62% |
| 2021-12-31 | R$104.28 Billion ≈ $20.46 Billion |
+14.60% |
| 2020-12-31 | R$90.99 Billion ≈ $17.85 Billion |
-12.89% |
| 2019-12-31 | R$104.45 Billion ≈ $20.49 Billion |
+8.79% |
| 2018-12-31 | R$96.02 Billion ≈ $18.84 Billion |
-4.45% |
| 2017-12-31 | R$100.49 Billion ≈ $19.72 Billion |
-10.33% |
| 2016-12-31 | R$112.07 Billion ≈ $21.99 Billion |
+9.46% |
| 2015-12-31 | R$102.38 Billion ≈ $20.09 Billion |
+6.71% |
| 2014-12-31 | R$95.94 Billion ≈ $18.83 Billion |
-- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevna… Read more